Latest guidelines for management of hypertension in pregnancy
Reading File
search_medical_text
hypertension in pregnancy classification diagnosis preeclampsia gestational hypertension guidelines
search_medical_text
antihypertensive treatment management hypertension pregnancy medications target blood pressure
search_medical_text
preeclampsia severe features eclampsia management delivery timing
GradeResponse
GradeResponse
GradeResponse
search_medical_text
preeclampsia severe features criteria HELLP syndrome diagnosis labs
search_medical_text
acute severe hypertension pregnancy IV labetalol hydralazine nifedipine treatment protocol
search_medical_text
magnesium sulfate eclampsia seizure prophylaxis aspirin preeclampsia prevention
GradeResponse
GradeResponse
Here is a comprehensive, guideline-based summary of the management of hypertension in pregnancy.
Management of Hypertension in Pregnancy
1. Classification
Hypertension in pregnancy is defined as BP ≥ 140/90 mmHg (confirmed on two readings at least 4 hours apart). It is classified into three main categories (Harrison's, p. 13631):
| Category | Definition |
|---|---|
| Chronic hypertension | Pre-existing or diagnosed before 20 weeks gestation |
| Gestational hypertension | New-onset BP ≥ 140/90 mmHg after 20 weeks, without proteinuria or end-organ features |
| Preeclampsia | New-onset hypertension after 20 weeks + proteinuria or end-organ damage |
2. Diagnosis of Preeclampsia
Preeclampsia requires new-onset hypertension (≥ 140/90 mmHg after 20 weeks) plus at least one of the following (Harrison's, p. 13632):
- Proteinuria (≥ 300 mg/24h or protein:creatinine ratio ≥ 0.3)
- Or, in the absence of proteinuria, evidence of end-organ damage (see severe features below)
Severe Features — any one qualifies:
| Feature | Threshold |
|---|---|
| Severe hypertension | BP ≥ 160/110 mmHg |
| Thrombocytopenia | Platelets < 100 × 10⁹/L |
| Renal insufficiency | Creatinine > 1.1 mg/dL |
| Liver impairment | Transaminases > 2× ULN |
| New-onset headache unresponsive to medication | — |
| Visual changes | — |
| Pulmonary edema | — |
| Severe epigastric pain (unremitting) | — |
HELLP Syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe subtype of preeclampsia and a major cause of maternal morbidity/mortality. Complications include CVA, hepatic capsule rupture, DIC, and placental abruption. (Harrison's, p. 13632)
3. Management by Category
A. Preeclampsia Without Severe Features
- Delivery at 37 weeks is recommended.
- Conservative management until 37 weeks with:
- Close monitoring for progression to severe features
- Careful fetal surveillance
- Restricted physical activity (Harrison's, p. 13633)
B. Preeclampsia With Severe Features
- Delivery is recommended in most cases.
- Expectant management may be considered only if:
- < 34 weeks gestation
- Managed in a tertiary hospital setting
- Patient remains clinically stable
- Indications for immediate delivery include any deteriorating maternal or fetal status. (Harrison's, p. 13633)
C. Eclampsia
- Seizures are managed with IV magnesium sulfate (4–6 g loading dose, then 1–2 g/hr maintenance).
- Magnesium sulfate is also used for seizure prophylaxis in preeclampsia with severe features.
- Delivery should be expedited once the patient is stabilized.
4. Antihypertensive Therapy
Threshold for Treatment
| Severity | Action |
|---|---|
| BP ≥ 140/90 mmHg | Initiate antihypertensive therapy (chronic or gestational HTN) |
| BP ≥ 160/110 mmHg | Urgent treatment mandatory in hospital setting |
Oral Agents for Chronic/Sustained Hypertension
First-line options (Harrison's, p. 13634):
- Labetalol (oral) — alpha and beta blocker; well established
- Extended-release nifedipine — calcium channel blocker; widely used
Target BP: 130–150 mmHg systolic / 80–100 mmHg diastolic — balancing maternal safety with uteroplacental perfusion.
Methyldopa is a traditional option but less preferred due to side effect profile.
Acute/Severe Hypertension (BP ≥ 160/110 mmHg)
Requires hospital management with continuous cardiotocographic monitoring and gradual BP reduction to < 160/110 mmHg (ESC Management of Cardiovascular Disease and Pregnancy, p. 60):
| Drug | Route | Notes |
|---|---|---|
| Nifedipine (oral) | PO | First-line; superior efficacy in some studies, widely available, lower cost |
| Labetalol | IV or PO | First-line; well-established safety profile |
| Methyldopa | PO | Alternative |
| Hydralazine | IV | Second-line only — less effective, more side effects than nifedipine/labetalol |
The choice depends on clinical context, route availability, expected delivery timing, and physician experience. (ESC CVD in Pregnancy Guidelines, p. 60)
Drugs to Avoid in Pregnancy
- ACE inhibitors (e.g., enalapril, lisinopril) — fetotoxic
- ARBs — associated with fetal renal dysgenesis, oligohydramnios
- Direct renin inhibitors (aliskiren)
5. Prevention
- Low-dose aspirin (75–150 mg/day) starting at 12–16 weeks is recommended for women at high risk of preeclampsia (prior preeclampsia, chronic hypertension, multifetal gestation, CKD, diabetes, autoimmune disease).
- Calcium supplementation (1.5–2 g/day) in women with low dietary calcium intake reduces risk of preeclampsia.
6. Postpartum Considerations
- Hypertension can persist or worsen in the first few days postpartum — monitoring is essential for at least 72 hours after delivery.
- Antihypertensives safe during breastfeeding: labetalol, nifedipine, enalapril (postpartum ACE inhibitors are permissible during breastfeeding).
- Women with a history of preeclampsia have increased long-term cardiovascular risk and should receive appropriate counseling and follow-up.
Key sources: Harrison's Principles of Internal Medicine, 21st Edition (pp. 13631–13634); ESC Guidelines on Management of Cardiovascular Disease during Pregnancy (p. 60).
This is a shared conversation. Sign in to Orris to start your own chat.